Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
Alimentary Pharmacology & Therapeutics · 2025-08 · 62 (3) · 300-318
DOI: 10.1111/apt.70228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 25.06.2025. Verfasst von Mengmeng Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Fir…. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Hematologic Neoplasms, Antibodies, Monoclonal, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 136 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Drug‐induced liver injury (DILI) is a leading cause of liver damage. It is especially prevalent in haematologic malignancies, complicating treatment regimens and posing a risk for severe outcomes such as acute liver failure. Antibody‐based therapies have significantly improved treatment outcomes. However, these therapies are increasingly associated with liver injury, posing challenges in clinical management.
Aims
This review aims to examine the DILI associated with antibody‐based therapies in haematologic malignancies, highlighting key mechanisms, risk factors, clinical management strategies, and identifying areas that require further research.
Methods
We conducted a comprehensive review of the literature on DILI induced by antibody‐based therapies, including monoclonal antibodies, antibody‐drug conjugates, and T‐cell redirecting antibodies, specifically in the context of haematologic malignancies.
Results
DILI associated with antibody‐based therapies varies from mild transaminase elevations to severe liver injury. Risk factors include pre‐existing liver disease, genetic predisposition, and therapy‐specific mechanisms such as immune‐mediated liver damage or direct hepatotoxic effects. Current management strategies involve routine liver function monitoring, dose modifications, and therapy discontinuation in severe cases. However, standardised guidelines remain lacking.
Conclusions
DILI remains a major challenge in the use of antibody‐based therapies for haematologic malignancies. While progress has been made in understanding risk factors and management strategies, further research is essential to optimise patient care and balance therapeutic efficacy with liver toxicity risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzho…
- Department of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Zhejiang, Hangzhou, China.
- School of Medicine, Hangzhou City University, Zhejiang, Hangzhou, China.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lin, M., Xie, Y., Wu, J., Zhang, C., Shi, S., Lin, N., Tong, X., & Li, Y. (2025). Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies. Alimentary Pharmacology & Therapeutics, 62(3), 300-318. https://doi.org/10.1111/apt.70228
Vancouver
Lin M, Xie Y, Wu J, Zhang C, Shi S, Lin N, et al. Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies. Alimentary Pharmacology & Therapeutics. 2025;62(3):300-318. doi:10.1111/apt.70228
BibTeX
@article{Lin2025,
author = {Lin, Mengmeng and Xie, Yaping and Wu, Jiahe and Zhang, Chong and Shi, Shanshan and Lin, Nengming and Tong, Xiangmin and Li, Yangling},
title = {Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {3},
pages = {300--318},
doi = {10.1111/apt.70228}
}
EUVIMED